Daratumumab is a monoclonal antibody used primarily to treat multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points about daratumumab:
Mechanism of Action: Daratumumab targets the CD38 protein on the surface of myeloma cells, helping the immune system to identify and destroy these cancer cells12.
Administration: It is administered as an intravenous infusion by a healthcare professional. The frequency of administration can vary, typically starting with weekly doses and then spacing out to every few weeks23.
Combination Therapy: Daratumumab can be used alone or in combination with other medications, such as lenalidomide, bortezomib, or dexamethasone, to enhance its effectiveness12.
Side Effects: Common side effects include infusion-related reactions, fatigue, nausea, back pain, fever, and cough. Serious side effects can include infections, low blood cell counts, and liver problems13.
Given your interest in biosimilars and monoclonal antibodies, daratumumab represents a significant advancement in the treatment of multiple myeloma. If you need more detailed information or have specific questions, feel free to ask!